Table 1.
The role of LINC00665 in different human cancers.
| Tumor Type | Assessed Cell Lines | Animals | Expression | Detection and Statistical Methods | Regulatory Mechanism | Effect In Vitro | Effect In Vivo | Ref. |
|---|---|---|---|---|---|---|---|---|
| Breast cancer | BC (MCF-7, MDA-MB-231, BT474, BT549, MDA-MB-468, and T47D); Normal (MCF-10A) | 10 SCID mice (5-week-old, female) | Upregulation | qRT-PCR; Student’s t-test | LINC00665/miR-379-5p/LIN28B | proliferation↑ migration↑ invasion↑ EMT↑ | tumor growth↑ | [10] |
| BC (MCF-7, MDA-MB-231, ZR-75-30, and MDA-MB-415); Normal (MCF-10A) | - | Upregulation | TCGA RNA-seq and qRT-PCR; Independent sample t-test |
- | proliferation↑ migration↑ invasion↑ EMT↑ | - | [11] | |
| BC (MCF-7 and MDA-MB-231); Normal (MCF-10A) | - | Upregulation | qRT-PCR and GEPIA; Student’s t-test and ANOVA | LINC00665/miR-3619-5p/CTNNB1 | proliferation↑ migration↑ invasion↑ cell cycle↑ apoptosis↓ | - | [12] | |
| - | - | Upregulation | TCGA RNA-seq and qRT-PCR; Student’s t-test and Chi-square test | - | cell cycle↑ DNA repair↑ | - | [9] | |
| BC (MCF-7, MDA-MB-231, and HCC-1937); Normal (MCF-10A) | 12 BALB/c nude mice (4-week-old, female) | Upregulation | TCGA RNA-seq and qRT-PCR; Student’s t-test, ANOVA, and Tukey post hoc tests | LINC00665/miR-551b-5p | proliferation↑ apoptosis↓ | tumor growth↑ | [13] | |
| Triple negative breast cancer | TNBC (BT549, Hs578T, and MDA-MB-231); Normal (MCF-10A and HEK293T) | 50 Nude mice (6–8-week-old, female) | Downregulation | qRT-PCR; two-tailed Student’s t-test | LINC00665/ CIP2A-BP/CIP2A |
migration↓ invasion↓ | tumor growth↓ | [5] |
| Prostate cancer | PC (LNCaP, PC-3, DU-145, and 22RV1); Normal (RWPE-1) | 10 BALB/c nude mice (4-week-old, female) | Upregulation | qRT-PCR; Student’s t-test and ANOVA | LINC00665/miR-1224-5p/SND1 | proliferation↑ migration↑ invasion↑ | tumor growth↑ | [14] |
| PC (PC-3, DU-145, 22RV1, and LNCaP) | 10 Nude mice (8-week-old, male) | Upregulation | qRT-PCR; Student’s t-test | LINC00665/ EZH2, LSD1/KLF2 |
proliferation↑ migration↑ | tumor growth↑ | [15] | |
| PC (PC3) | - | Upregulation | TCGA RNA-seq and qRT-PCR; two-tailed Student’s t-test | - | DNA repair↑ radiosensitivity↓ | - | [16] | |
| Ovarian cancer | OC (A2780, OVCAR3, CAOV3, and SKOV3); Normal (IOSE80) | - | Upregulation | qRT-PCR; Student’s t-test and Pearson correlation test | LINC00665/miR-34a-5p/E2F3 | proliferation↑ migration↑ invasion↑ | - | [17] |
| - | - | Upregulation | TCGA RNA-seq and GTEx RNA-seq | LINC00665/ EDEM1, CAPNS1, SQSTM1, SERPINA1 |
- | - | [18] | |
| - | - | Upregulation | GEO RNA-seq | LINC00665/miR-146a-5p/CXCR4 | - | - | [44] | |
| High-grade serous ovarian cancer | - | - | Upregulation | TCGA RNA-seq and GTEx RNA-seq | LINC00665/miR-449b-5p/RRAGD | - | - | [19] |
| Cervical cancer | CA (HeLa) | 10 BALB/c immuno-deficient mice (female) | Upregulation | RNA-seq and qRT-PCR; ANOVA | LINC00665/ CTNNB1/(Wnt/β-catenin signaling pathway) |
proliferation↑ migration↑ invasion↑ EMT↑ | tumor growth↑ | [20] |
| Uterine corpus endometrial cancer | UCEC (RL-95-2, Ishikawa, HEC-1B, KLE, and HHUA) | 12 Mice (8-week-old, female) | Upregulation | qRT-PCR; Student’s t-test and ANOVA | LINC00665/ HMGA1 |
proliferation↑ migration↑ invasion↑ apoptosis↓ | tumor growth↑ | [21] |
| Gastric cancer | GC (MKN28, BGC-823, SGC-7901, AGS, and HGC-27); Normal (GES-1) | 12 Nude mice (6-week-old, male) | Upregulation | qRT-PCR; two-tailed Student’s t-test and ANOVA | LINC00665/(Wnt/β-catenin signaling pathway) | proliferation↑ migration↑ invasion↑ apoptosis↓ | tumor growth↑ | [22] |
| GC (AGS, SGC-7901, HGC27, MGC-803, MKN-45, and BGC-823); Normal (GES-1) | - | Upregulation | qRT-PCR; Student’s t-test and ANOVA | LINC00665/miR-149-3p/RNF2 | proliferation↑ migration↑ invasion↑ | - | [23] | |
| GC (AGS, MKN45, HGC27, MKN28, and SGC7901); Normal (GES) | BALB/c nude mice (6-week-old) | Upregulation | TCGA RNA-seq and qRT-PCR; Unpaired Student’s t-test and ANOVA | LINC00665/ TGF-β/Smad-2, α-SMA |
EMT↑ migration↑ invasion↑ cell cycle↑ apoptosis↓ | tumor growth↑ | [24] | |
| GC (SGC-7901, AGS, and HST2); Normal (GES) | - | Upregulation | qRT-PCR; Student’s t-test and ANOVA | LINC00665/miR-379-5p/GRP78 | proliferation↑ apoptosis↓ | - | [25] | |
| Hepatocellular carcinoma | HCC (Huh-7 and HepG2) | - | Upregulation | TCGA RNA-seq; Student’s t-test, ANOVA, Dunnett’s multiple comparisons test, Wilcoxon tests, and nonparametric Mann–Whitney U-test | NF-κB/ LINC00665/ PKR/NF-κB loop |
proliferation↑ | tumor growth↑ | [26] |
| - | - | Upregulation | TCGA RNA-seq, GEO RNA-seq and qRT-PCR; Independent sample t-tests | - | - | - | [3] | |
| HCC (Huh-7, HepG2, HCCLM6, MHCC-97H, and Hep3B); Normal (HL-7702) | 24 BALB/c nude mice (4–6-week-old, female) | Upregulation | qRT-PCR; Student’s t-test and ANOVA | LINC00665/miR-186-5p/MAP4K3 | proliferation↑ apoptosis↓ autophagy↓ | tumor growth↑ | [27] | |
| Colorectal cancer | CRC (DLD-1, SW480, KM12, SW116, and SW620); Normal (NCM460) | - | Upregulation | qRT-PCR; Student’s t-test and ANOVA | LINC00665/miR-9-5p/ATF1 | proliferation↑ migration↑ invasion↑ apoptosis↓ | - | [28] |
| CRC (SW620, LOVO, HCT-116, and SW480); Normal (NCM460) | Nude mice (Female) | Upregulation | qRT-PCR; Student’s t-test and ANOVA | LINC00665/miR-214-3p, U2AF2/ CTNNB1/(Wnt/β-catenin signaling pathway) |
proliferation↑ migration↑ invasion↑ apoptosis↓ | tumor growth↑ | [29] | |
| CRC (DLD1, RKO, HCT116, LOVO, SW480, and NCM460) | - | Upregulation | qRT-PCR; Student’s t-test and ANOVA | LINC00665/miR-126-5p/PAK2, FZD3 | proliferation↑ invasion↑ apoptosis↓ | - | [30] | |
| Cholangiocarcinoma | CCA (SNU-1196, SNU-1079, SNU-308, SNU-245, SNU-478, and SNU-869) | 18 Nude mice | Upregulation | qRT-PCR and lncRNA microarray analysis; two-tailed Student’s t-test and ANOVA | LINC00665/miR-424-5p/BCL9L/(Wnt/β-catenin signaling pathway) | proliferation↑ drug resistance↑ EMT↑ stemness↑ apoptosis↓ | Drug resistance↑ | [8] |
| Non-small cell lung cancer | NSCLC (A549, H520, H1299, SPC-A1, and SK-MES-1) | 24 BALB/c nude mice | Upregulation | qRT-PCR and lncRNA microarray analysis; two-tailed Student’s t-test and ANOVA | LINC00665/miR-138-5p/E2F3 | proliferation↑ invasion↑ | tumor growth↑ | [31] |
| LUAD (PC9) | 24 Athymic BALB/c nude mice (5-week-old, male) | Upregulation | qRT-PCR; Student’s t-test | LINC00665/ EGFR/(PI3K/AKT signaling pathway) |
proliferation↑ drug resistance↑ migration↑ cell cycle↑ apoptosis↓ | tumor growth↑ Drug resistance↑ | [6] | |
| NSCLC (PC9, SPC-A1, H1975, H1299, and A549); Normal (16HBE) | 24 BALB/c nude mice (4–5-week-old, male) | Upregulation | qRT-PCR; Student’s t-test, Wilcoxon test, and Chi-square test | LINC00665/ EZH2/ CDKN1C |
proliferation↑ migration↑ cell cycle↑ drug resistance↑ apoptosis↓ | tumor growth↑ Drug resistance↑ | [7] | |
| Lung adenocarcinoma | NSCLC (A549, H1299, 16HBE, and D551) | 30 BALB/c athymic nude mice (4-week-old, female) | Upregulation | qRT-PCR; Student’s t-test, multiple Student’s t-test, and nonparametric Mann–Whitney U-test | LINC00665/ YB-1/ANGPT4, ANGPTL3, VEGFA |
proliferation↑ angiogenesis↑ | angiogenesis↑ | [32] |
| NSCLC (A549, H1299, H1650, H520, SPC-A1, and SK-MES-1); Normal (16HBE) | 20 BALB/c athymic nude mice (4-week-old, female) | Upregulation | qRT-PCR; Student’s t-test and nonparametric Mann–Whitney U-test | SP1/ LINC00665/miR-98-5p/AKR1B10/(ERK signaling pathway) |
proliferation↑ migration↑ invasion↑ EMT↑ | tumor growth↑ | [1] | |
| LUAD (SK-LU-1 and Calu-3) | 15 BALB/c nude mice (6–8-week-old, male) | Upregulation | qRT-PCR and GEPIA; two-tailed Student’s t-test, ANOVA and Tukey’s tests | LINC00665/miR-181c-5p/ZIC2 | proliferation↑ invasion↑ | tumor growth↑ | [33] | |
| LUAD (HBE, A549, H1299, H1975, PC9, and SPC-A1) | 10 BALB/c nude mice (male) | Upregulation | qRT-PCR; Student’s t-test and ANOVA | LINC00665/miR-195-5p/MYCBP | proliferation↑ invasion↑ cell cycle↑ apoptosis↓ | tumor growth↑ metastasis↑ | [34] | |
| - | - | Upregulation | GEO RNA-seq | LINC00665/miR-let-7b/CCNA2 | - | - | [35] | |
| Glioma | Glioma (U251 and U87); Normal (NHA) | BALB/c athymic nude mice(4-week-old) | Downregulation | qRT-PCR; Student’s t-test and ANOVA | TAF15/ LINC00665/ MTF1, YY2/ GTSE1 |
proliferation↓ migration↓ invasion↓ apoptosis↑ | tumor growth↓ | [43] |
| Glioma (U87 MG, LN229, A172, U373, and U251); Normal (NHA) | 6 Specific pathogen-free mice (4-week-old) | Upregulation | TCGA RNA-seq and qRT-PCR; Student’s t-test and ANOVA | LINC00665/miR-34a-5p/AGTR1 | proliferation↑ migration↑ invasion↑ | tumor growth↑ | [36] | |
| Thymic epithelial tumors | - | - | Upregulation | TCGA RNA-seq | LINC00665/miR-140/MYO10 & LINC00665/miR-3199/WASF3 | - | - | [37] |
| Osteosarcoma | Osteosarcoma (143B, U2OS, MG-63, and Saos-2); Normal (hFOB1.19) | - | Upregulation | qRT-PCR; Student’s t-test, ANOVA, and Dunnett’s test | LINC00665/miR-3619 | proliferation↑ migration↑ invasion↑ | - | [38] |
| Osteosarcoma (MG-63, U2OS, 143B, and Saos-2); Normal (hFOB) | - | Upregulation | qRT-PCR; Student’s t-test and ANOVA | LINC00665/miR-708-5p, miR-142-5p/RAP1B | proliferation↑ migration↑ invasion↑ | - | [2] | |
| Acute myelocytic leukemia | MM (MM.1S, U266, RPMI-8226, KM3, and H929); Normal (nPCs) | - | Upregulation | qRT-PCR; Student’s t-test and ANOVA | LINC00665/miR-214-3p/PSMD10, ASF1B | proliferation↑ apoptosis↓ | - | [39] |
| Melanoma | Melanoma (A375, M21, A2058, and A-875) | BALB/c nude mice (6-week-old, male) | Upregulation | qRT-PCR; Student’s t-test and ANOVA | LINC00665/miR-224-5p/VMA21 | proliferation↑ migration↑ | - | [40] |
| Acute myelocytic leukemia | AML (KG1, U937, NB4, and HL60); Normal (HS-5) | - | Upregulation | qRT-PCR and GEPIA; Student’s t-test, ANOVA, and Dunnett’s test | LINC00665/miR-4458-5p/DOCK1/Rac1 | proliferation↑ migration↑ adhesion↑ apoptosis↓ | - | [41] |
| T cell acute lymphoblastic leukemia | T-ALL (MOLT-4 and CCRF-CEM); Normal (PBMC) | - | Upregulation | qRT-PCR and GEPIA; Student’s t-test, ANOVA, and Bonferroni post hoc test | LINC00665/miR-101 | viability↑ migration↑ adhesion↑ | - | [42] |
SCID, Severe combined immune deficiency; EMT, Epithelial mesenchymal transformation; qRT-PCR, quantificational real-time polymerase chain reaction; TCGA, The cancer genome atlas; RNA-seq, RNA sequencing; GEPIA, Gene expression profiling interactive analysis; ANOVA, Analysis of variance; GEO, Gene expression omnibus; ↑, Promotion; ↓, Inhibition.